Life Edit Therapeutics
Hui-Chia Yu-Kemp is a Senior Scientist at Life Edit Therapeutics since April 2021, previously holding the position of Scientist II in Protein Chemistry. Prior experience includes a role as a Postdoctoral Fellow at the University of North Carolina at Chapel Hill from March 2017 to April 2021, where research focused on the mechanisms by which epithelial cells alter shape while maintaining tissue integrity, utilizing tissue culture and Drosophila models to explore the uncharacterized role of myosin in actin cytoskeleton organization. Hui-Chia Yu-Kemp earned a Doctor of Philosophy in Cell and Developmental Biology from the University of Illinois Urbana-Champaign, a Bachelor of Science in Life Science from National Taiwan University, and a Master's degree in Structural Biology and Biochemistry from National Yang Ming University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.